AHMEDABAD,4^th November: Alembic Pharmaceuticals Limited reported its consolidated financial results for the second quarter and half year ended 30th September 2025.

Financial Highlights for Q2FY26

• Revenue from operations increased by 16% to Rs.1,910 Cr.
• EBITDA increased by 26% to Rs. 325 Cr
• EBITDA Margin at 17% of revenue
• Reported Profit After Tax at Rs.185 Cr. up by 20%.

Operational Highlights India Branded Business

• India Branded Business delivered a 5% YoY growth, reaching ₹639 Cr in revenue for the quarter.
• Gynaecology, Ophthalmology and Animal healthcare segments have demonstrated accelerating performance.
• Cough & Cold segments grew in line with market performance, with robust operational execution.
• Successfully introduced 2 new products during the quarter.

International Business

• US Generics grew by 21% to Rs. 566 Cr. for the quarter.
• 3 Launches in the US market during the quarter.
• Ex-US International Generics grew by 31% to Rs. 392 Cr. for the quarter.
• 6 ANDA approvals received during the quarter, 226 Cumulative ANDA approvals.

API Business

• API business grew by 15% to Rs. 261 Cr. for the quarter.

The summary of Total Revenue is as under:

(Rs in Cr.)

 (Disclaimer: The information provided here is investment advice only. Investing in the markets is subject to risks and please consult your advisor before investing.)

(સ્પષ્ટતા: અત્રેથી આપવામાં આવતી તમામ પ્રકારની માહિતી કોઇપણ પ્રકારે રોકાણ/ ટ્રેડીંગ માટેની સલાહ નથી. બજારોમાં રોકાણ જોખમોને આધીન છે અને રોકાણ કરતા પહેલા કૃપા કરીને તમારા સલાહકારની સલાહ લો.)